ArticleJournal of clinical medicine2024

Inflammatory Markers Significantly Increased in Patients Treated with Obinotuzumab for Lymphoproliferative Diseases.

Krzysztof Gawronski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.